Q: Is compounded tirzepatide safe?

What the FDA records show

A:An estimated 5 million people in the US use compounded GLP-1 drugs such as tirzepatide, Time reported in 2026, citing a Gallup poll.¹ Still, compounded tirzepatide is not FDA-approved, and FDA records show sterility, strength, and dosing problems at some compounders. Tirzepatide is the active ingredient in Eli Lilly's Mounjaro and Zepbound. A compounded version of a drug is a customized medication created by a licensed pharmacist who alters or combines ingredients to meet the specific medical needs of a patient, and it is not the same as a generic medication.² In the FDA's words, "Generic drugs are approved by FDA prior to marketing, while a compounded drug is not approved by FDA." Therefore, it is false or misleading to describe a compounded drug as FDA-approved or as clinically proven to match the approved drug.^3,4

Compounded GLP-1 drugs remain allowed when the approved drug doesn't meet a patient's needs, for example when a patient needs a lower dose or is allergic to an ingredient.⁵ Despite these requirements, a secret-shopper study published in JAMA Health Forum in 2026 found that 86.7% of 75 weight-loss clinics and med spas in Oklahoma and West Virginia still sold compounded tirzepatide from August to October 2025, after the FDA had declared the shortage over.^6,7 Of the 75, 58.7% sold compounded versions with added ingredients, most often B vitamins. Lead author Michael J. DiStefano, of the University of Colorado Anschutz Medical Campus, said compounding had shifted toward products "ostensibly tailored to meet specific patient needs."⁶

FDA records show sterility and strength problems at some compounders. Apothecary Pharma, a North Carolina compounder, recalled 22 vials of compounded tirzepatide in September 2026 because their sterility could not be assured. The National Association of State Pharmacy Associations summarized FDA findings at Boothwyn, a Pennsylvania compounder, including two tirzepatide products at about 87% and 89% of labeled potency.^3,8 For more about the recall, including the lot numbers, see our recall answer.

Dosing is also a risk. The FDA has reported patients taking 5 to 10 times the intended dose of compounded semaglutide, sold in multidose vials, after providers converted milligrams to units or milliliters incorrectly. The recalled compounded tirzepatide was also sold in multidose vials.^9,3 For more about checking stock against recalled lots and the claims the FDA calls misleading, see our compounded injectables review.